Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
about
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung CancerExploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell cultureTargeted therapies in non-small cell lung carcinoma: what have we achieved so far?A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinomaA phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.Inhibitors of mTOR.Targeted therapy of non-small-cell lung carcinoma.Molecular-targeted agents combination therapy for cancer: developments and potentials.Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.The Biological Role of PI3K Pathway in Lung Cancer.Oncogenic driver mutations in lung cancer.Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells.Targeting signaling pathways in lung cancer therapy.Lung cancer: New biological insights and recent therapeutic advances.Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
P2860
Q27853128-0BD72687-4191-478C-81D6-C7D4EC331884Q33401499-86985560-3ACD-465C-B29E-C3A3733FD070Q33405880-52A0EFFF-0DC9-4C9C-BA7A-987198E6CB16Q33407021-7A3D5E3B-3A2A-49AF-B988-E6EFEE74BEEBQ33409908-7A0D80B6-452C-4970-ADDC-7ACCF24443D2Q34019169-8000C24D-F10A-47BE-A5E8-43EC5094F6F2Q35463464-0388B488-83CB-44CA-9DA7-2598C62B15B2Q35679387-6B67ACBC-42BB-4B2A-B22B-EFC68AED4E96Q36999705-7EC42A89-1BAC-459C-A215-7392F91F37B3Q37248229-BA0060F6-F35C-4C17-A557-E06E1B9EB342Q37483253-60AD3238-1DFF-43A9-9220-70F880C508EDQ37819463-C62F56AD-9D4B-44C8-812F-287268706429Q37897792-03BDD3E7-307E-4EDD-8EEC-E19BF90EEBDCQ38104670-6075F9D5-D23E-4DB9-A736-1914369A8E7BQ38148583-03A49D40-1D0D-4ECE-A76A-27C49146AC48Q38166599-B93A6C52-BE40-43C8-B665-E140DD5CB024Q38846405-CB98F979-FEBF-432C-A7DF-6AC496F14D7AQ39578075-701CA762-00BB-4BC0-A9BE-AFFB52304355Q46006150-591F8825-880F-43EC-8BB2-E14EE9D11891Q46049056-C5452243-2DD0-46CD-A027-2D169839E839Q51122180-9F194E81-B4AE-4B2B-A757-FAFEFD0CD6EE
P2860
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@ast
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@en
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@nl
type
label
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@ast
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@en
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@nl
prefLabel
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@ast
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@en
Phase 1 and pharmacokinetic st ...... ory nonsmall cell lung cancer.
@nl
P2093
P2860
P356
P1433
P1476
Phase 1 and pharmacokinetic st ...... tory nonsmall cell lung cancer
@en
P2093
Dong M Shin
Fadlo R Khuri
Merrill J Egorin
Mourad Tighiouart
Nabil Saba
R Donald Harvey
Sandra Strychor
Shi-Yong Sun
P2860
P304
P356
10.1002/CNCR.25264
P407
P577
2010-08-01T00:00:00Z